SRC1 gene regulation in endocrine resistant breast cancer cells
Ontology highlight
ABSTRACT: The development of breast cancer resistance to endocrine therapy results from an increase in cellular plasticity leading to the development of a steroid independent tumour. The p160 steroid coactivator protein SRC-1, through interactions with developmental proteins and other non-steroidal transcription factors drives this tumour adaptability. Here, using discovery studies we identify ADAM22, a non-protease member of the ADAMs family, as a direct target of SRC-1, independent of estrogen receptor(ER). Molecular, cellular, in vivo and clinical studies confirmed SRC-1 as a regulator of ADAM22 and established a role for ADAM22 in endocrine resistant tumour progression. ADAM22 has the potential to act as a therapeutic drug target and a companion predictive biomarker in the treatment of endocrine resistant breast cancer.
ORGANISM(S): Homo sapiens
PROVIDER: GSE28645 | GEO | 2012/01/11
SECONDARY ACCESSION(S): PRJNA138957
REPOSITORIES: GEO
ACCESS DATA